Research Progress on the Core Metabolic Pathological Mechanisms and Treatment Strategies of Polycystic Ovary Syndrome

Corresponding author: WANG Peijuan, pjwang8822@163.com

DOI: 10.12201/bmr.202512.00007

•  

  Abstract: Polycystic ovary syndrome (PCOS) is a highly heterogeneous reproductive endocrine and metabolic disorder. The understanding of its pathology has shifted from a focus on abnormalities in the reproductive axis to a new paradigm centered on metabolic dysregulation. The pathogenesis of PCOS is closely linked to key mechanisms including insulin resistance, the vicious cycle of lipid metabolism disorders and chronic inflammation, the regulatory role of the gut microbiota-metabolism axis, and androgen-driven metabolic reprogramming. Based on these mechanisms, this review explores a range of metabolic intervention strategies—from lifestyle modifications and pharmacotherapy to emerging therapies—to provide a theoretical foundation for the clinical management of PCOS.

  Key words: Polycystic Ovary Syndrome; Pathological Mechanisms; Metabolic Dysfunction; Therapeutic Strategies

  Submit time: 2 December 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• Liu Lingyan. Ferroptosis and endoplasmic reticulum stress in polycystic ovary syndrome and related potential therapeutic targets. 2025. doi: 10.12201/bmr.202507.00042

  Zhang Han, Chu Mengyuan, Xu Kaikai, Xiang Xin, Yan Ying. Progress in Mechanism of Action of Isthmin1 Protein in Polycystic Ovary Syndrome. 2024. doi: 10.12201/bmr.202411.00004

  LI Xiao, YAO Hongmei. Ovarian steroid cell tumor with polycystic ovary syndrome：a case report. 2025. doi: 10.12201/bmr.202505.00034

  Zhenghaijuan, NiuXiaohan. Research Progress of CCR and metabolic syndrome and its related diseases. 2025. doi: 10.12201/bmr.202501.00048

  沈思齐, Wu Luyao, Fang Haoxiang, Shao Yanfei. Mechanism and research progress of flavonoids in prevention and treatment of nephrotic syndrome. 2025. doi: 10.12201/bmr.202511.00086

  Zhang zhenwen. Effects of SGLT2 inhibitors on the metabolic syndrome and its components. 2025. doi: 10.12201/bmr.202503.00002

  Liu Wei, Cao Jun, Zhang Xiao Mei, Wang Bao Hua, Zhu Hong Qing. Effects of Shugan Huoxue Yishen decoction on homocysteine, inflammatory factors and endothelial function in patients with metabolic syndrome-related erectile dysfunction. 2025. doi: 10.12201/bmr.202508.00012

  JIANG Yunlan, LI Le, CHEN Hong, WANG Jing, ZHANG Mengjie, BAI Xiaoyu, WU Senlin. Risk factors for metabolic syndrome in hospitalized schizophrenia patients in China: a Meta-analysis. 2025. doi: 10.12201/bmr.202504.00071

  XuHong. Advances in the treatment of osteopenia-seropathic obesity syndrome in the elderly. 2024. doi: 10.12201/bmr.202411.00064

  wangyixuan, wusiyi, fangyue, zhoulushan, songxiaobo, leilei, chenxiaofei, dingcaifei, wangchenye. . 2024. doi: 10.12201/bmr.202407.00047

• ID	Submit time	Number	Download
  1	2025-11-19	10.12201/bmr.202512.00007V1	Download

• Public  Anonymous  To author only Submit Comments